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In this and the next issue of Critical Care, John Haddad [1,2]
presents a comprehensive review on the contributions of
transcription factors to lung injury. The topic is large and ever
changing, and the complete coverage of nuclear factor-κB
(NF-κB) and hypoxia-inducible factor (HIF)-1α is spread over
two issues. In critical care approximately 80% of patients
with sepsis develop an acute lung injury [3]. The majority of
these patients progress to the point at which they require
intubation and mechanical ventilation, with an associated
high mortality. Recent studies [4] have demonstrated that low
tidal volume (6 ml/kg) ventilation strategies dramatically
reduce this mortality. However, many other clinical trials of
various treatments have failed at either reducing the lung
injury or accelerating the healing to the end-point of reduced
mortality [5].
In this age of genomics and proteomics we continue to
explore the association of gene and environment. With
respect to lung injury, we need to identify and understand the
mechanisms that predispose patients to the excessive
inflammation resulting from an overactive innate immune
response that characterizes sepsis and lung injury. These
include stimuli, signal transduction (receptors, enzyme
cascades, transcription factors), gene(s) response and the
measured clinical phenotype. John Haddad [1,2], in his two-
part review, identifies many ‘clinical stimuli’ in cell culture,
animal model and patient studies representing an oxidative
stress that can generate a response via NF-κB or HIF-1α
dependent signalling.
Nuclear factor-κ κB: response to stimuli
NF-κB was originally described in B lymphocytes [6], but it is
now recognized as a member of the Rel family of
transcription factors and is a critical response element in
many cytokine-dependent events or inflammatory conditions
[7]. As a result of this link, NF-κB has become a major target
for new therapeutic approaches in such clinical disease
states as asthma, cancer, arthritis, and cardiovascular and
neurodegenerative conditions. Haddad [1,2] discusses the
roles of critical care conditions such as hyperoxia,
haemorrhage and resuscitation; the ‘stress response’ to
illness (interleukin-6, interleukin-8, tumour necrosis factor,
RANTES [regulated upon activation, normal T cell expressed
and secreted]); and mechanical ventilation and
ischaemia/reperfusion. In all of these conditions free radical
production can activate NF-κB. These dynamic variations in
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Abstract
The role of oxidative stress in regulating transcription factors and specific gene responses in critical
illness is a new and emerging area. A better understanding of the proinflammatory oxidant stimuli of
reactive oxygen species generation and how this generates the clinical phenotype of acute lung injury
by regulating gene expression may allow the development of new therapeutic strategies. In his review
John Haddad describes the present data and role for transcription factors nuclear factor-κB and
hypoxia-inducible factor-1α in acute lung injury.
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cellular redox or oxidative stress, if in disequilibrium, may
regulate gene expression and lead to apoptosis (cell death
without inflammation), inflammation and lung injury.
Hypoxia-inducible factor-1α α: role in
hypoxaemia-initiated lung injury
The master regulatory element of hypoxic conditions and
adapting oxidative stresses to gene expression is HIF-1α
[8–10]. HIF-1 consists of two subunits. HIF-1α, a DNA-
binding protein, has increased stability and binding in hypoxic
conditions and is degraded rapidly in normoxia. The
accumulation of the α-subunits allows for αβ heterodimer
formation and translocation into the nucleus during hypoxia.
This process leads to selective upregulation of genes whose
products are involved in hypoxia and inflammatory lung injury.
These include erythropoietin, vascular endothelial growth
factor (VEGF) and glucose transporter [9–11]. Work by
Haddad [12,13] has demonstrated that proinflammatory
cytokines also activate HIF-1α stability and DNA binding.
This effect was most profound in hypoxic conditions and was,
in fact, greater than that in hypoxaemia alone. It is felt that
HIF-1α, via its action on VEGF expression, is directly related
to lung injury by endothelial barrier dysfunction mediated by
VEGF and recognized clinically as increased pulmonary
vascular permeability. Haddad [1,2] discusses in detail how
hypoxia and inflammatory stimuli initiate many signalling
cascades via HIF-1α to generate a response phenotype to
these oxidative stresses.
Conclusion
Understanding the molecular signalling that couples oxidative
stresses via NF-κB or HIF-1α to acute lung injury should
generate new therapeutic options. Haddad [1,2] discusses
the rationale for the use of tyloxapol to reduce
proinflammatory cytokines, N-acetyl cysteine (a glutathione
precursor) to reduce neutrophil-associated alveolitis in
chronic conditions such as cystic fibrosis, and the use of
pyrrolidine dithiocarbamate in transplantation to reduce
neutrophil-associated oxidant lung injury. Two new
compounds, isohelenin and lisofylline, a phosphodiesterase
inhibitor, are described as being able to reduce
proinflammatory cytokines and ameliorate oxidant lung injury
in animal models. As exciting as this emerging field is, with its
predictable contribution to future ‘bench to bedside’
discussions, a more complete mechanistic understanding
and future clinical trials will assist in the realization of
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